<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01397877</url>
  </required_header>
  <id_info>
    <org_study_id>ENDOPIK</org_study_id>
    <nct_id>NCT01397877</nct_id>
  </id_info>
  <brief_title>GINECO-EN102b - BKM120 as Monotherapy in the Treatment of Initial or Recurrent Metastatic Endometrial Cancer</brief_title>
  <acronym>ENDOPIK</acronym>
  <official_title>Phase 2 Multicenter Study to Assess the Safety and Efficacy of BKM120 as Monotherapy in Treatment of Initial or Recurrent Metastatic Endometrial Cancer After 1st Line Therapy in Patients Who Cannot Undergo Local Surgery and/or Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARCAGY/ GINECO GROUP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ARCAGY/ GINECO GROUP</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to determine the clinical efficacy of BKM120 as monotherapy in the treatment of
      initial or recurrent metastatic endometrial cancer after first line radio chemotherapy.

      Clinical efficacy will be determined by the non-progression rate at 3 or 2 months depending
      on the group of patients. The primary endpoint is the non-progression rate at 3 months (12
      weeks) for the patient group whose disease is painless (low grade tumor = stratum 1) and the
      non-progression rate at 2 months (8 weeks) for the group of patients with an aggressive
      disease (high grade tumor = stratum 2).

      Disease progression is defined by the RECIST 1.1 criteria
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Efficacy</measure>
    <time_frame>3 months</time_frame>
    <description>To determine the clinical efficacy of BKM120 as monotherapy in the treatment of initial or recurrent metastatic endometrial cancer after first line radio chemotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety according to CTCAE v4.0 criteria and mood questionnaires : PHQ-9 and GAD-7</measure>
    <time_frame>Patient will be followed for the duration of the study, an expected average of 75 days</time_frame>
    <description>To assess patient safety and the tolerance of BKM120 administered as monotherapy at the daily dose of 100 mg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: PFS</measure>
    <time_frame>6 months</time_frame>
    <description>To evaluate progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: ORR</measure>
    <time_frame>Patient will be followed for the duration of the study, an expected average of 75 days</time_frame>
    <description>To evaluate the objective response rate according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: overall survival</measure>
    <time_frame>Patients will be followed for an expected average of 1 year and 75 days</time_frame>
    <description>To evaluate overall survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: duration of response</measure>
    <time_frame>Patients will be followed for an expected average of 1 year and 75 days</time_frame>
    <description>To evaluate the duration of the response. For patients in complete remission, the duration of the response will be calculated from the day on which a complete response is determined for the first time up to progression.
For patients in partial remission, the duration of the response will be the overall response period calculated from the administration of the first treatment cycle up to the date of progression.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>stratum 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with low grade disease (grade 1 or 2) with positive or negative mutational status</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BKM120</intervention_name>
    <description>per os, 60mg/j, until progression or unacceptable toxicity</description>
    <arm_group_label>stratum 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female ≥ 18 years

          -  ECOG ≤ 2

          -  Histologically confirmed endometrial cancer

          -  Not eligible for exclusive curative treatment by surgery and/or radiotherapy

          -  Initial metastatic endometrial cancer not treated with chemotherapy or radiotherapy
             prior to inclusion OR

          -  Recurrent endometrial cancer previously treated with adjuvant CT and RT, presenting
             with a disease-free interval of at least 12 months

          -  Presence of one or more measurable lesion(s) outside the irradiated areas

          -  Availability at inclusion of samples of tumor tissue (a block or at least 20 unstained
             slides) for tumor sub-classification and for routine molecular analysis

          -  Satisfactory biological functions: PNN ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L,
             hemoglobin ≥ 9.0 g/dL, INR ≤ 2, standard normal values for potassium, calcium and
             magnesium, serum creatinine ≤ 1.5 x ULN or creatinine clearance &gt; 50 mL/min, ALT and
             AST within normal range (or ≤ 3.0 x ULN if liver metastases present), Alkaline
             phosphatase ≤ 2.5 x ULN, serum bilirubin within normal range (or ≤ 1.5 x ULN if liver
             metastases present; or total bilirubin ≤ 3.0 x ULN with direct bilirubin within normal
             range in patients with well documented Gilbert Syndrome), fasting glycemia ≤ 120 mg/dL
             or ≤ 6.7 mmol/L

          -  Life expectancy 3 months

          -  Post menopausal woman with at least 12 months of natural (spontaneous) amenorrhea

          -  Negative serum pregnancy test ≤ 72 hours prior to initiating treatment for woman of
             child-bearing potential

          -  Consent form signed before any procedure performed

        Exclusion Criteria:

          -  Previous treatment with PI3K inhibitors and/or mTOR

          -  Presence of symptomatic CNS metastases. Patient must have completed any prior
             treatment for CNS metastases ≥ 28 days and, if on corticosteroid therapy, should be
             receiving a stable low dose

          -  Concomitant presence or history of another malignant tumor in the past 3 years prior
             to inclusion (except spinocellular or cutaneous basal cell epithelioma or
             non-melanomatous skin cancer treated successfully)

          -  Suffering from mood disorders based on an evaluation by the investigator or a
             psychiatrist OR with a given score according to the PHQ-9 or GAD-7 mood evaluation
             scale (cf protocol)

          -  Concomitant administration of another approved or investigational anticancer agent

          -  Pelvic and/or para-aortic radiotherapy within ≤ 28 days prior to inclusion or
             persistent side effects from this treatment on implementation of the selection
             procedures

          -  Major surgery during the 28 days prior to starting investigational drug or persistent
             side effects from surgery

          -  Uncontrolled diabetes (HbA1c &gt; 8 %)

          -  Presence of an active heart disease, especially: LVEF &lt; 50 % determined by MUGA or
             ECHO, QTc &gt; 480 msec on ECG recorded during selection (with QTcF formula), angina
             warranting the administration of anti-angina treatment, ventricular arrhythmia except
             for benign premature ventricular contractions, supraventricular and nodal arrhythmias
             warranting a pacemaker or not controlled by a treatment, conduction anomalies
             warranting a pacemaker, valvular disease with documented involvement of cardiac
             function, symptomatic pericarditis

          -  History of heart disease

          -  Currently receiving treatment to prolong QT interval accompanied by a known risk of
             triggering wave burst arrhythmia. Impossible to stop treatment or to replace it before
             starting study medication

          -  GI dysfunction or disease that could significantly interfere with absorption of BKM120

          -  Chronic treatment with corticosteroids or other immunosuppressants

          -  Any other severe and/or uncontrolled concomitant disease, which is likely to
             contraindicate the patient's participation

          -  Known treatment non-compliance

          -  Currently receiving treatment known to be inhibitors or moderate and strong inducers
             of isoenzyme CYP3A. Impossible to stop this treatment or to replace it with a
             different treatment before starting the study product

          -  Severe pneumonitis

          -  Grade ≥ 3 biological anomalies

          -  Known history of HIV infection

          -  Pregnant woman or nursing mother
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle Ray-Coquard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GINECO - Centre Léon Bérard</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique Bonnefon</name>
      <address>
        <city>Ales</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Papin</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Ste Catherine</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Blois</name>
      <address>
        <city>Blois</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Tivoli</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Bordeaux Nord</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>centre Francois baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre jean Perrin</name>
      <address>
        <city>Clermont Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Civils de Colmar</name>
      <address>
        <city>Colmar</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges François leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Group Hospitalier Mutualiste de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Michallon - CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHD Les Oudairies</name>
      <address>
        <city>la Roche sur Yon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital André Mignot</name>
      <address>
        <city>Le Chesnay</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre jean Bernard</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dupuytren</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Prové Clairval</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRLC Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupement de coopération sanitaire</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'oncologie de Gentilly</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Catherine de Sienne</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Caremeau</name>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Valdegour</name>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Hotel Dieu</name>
      <address>
        <city>Paris</city>
        <zip>75004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Frederic Joliot</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Armoricaine de Radiologie</name>
      <address>
        <city>Saint Brieuc</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital rené Huguenin</name>
      <address>
        <city>St Cloud</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO René Gauducheau</name>
      <address>
        <city>St Herblain</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Etienne DOLET</name>
      <address>
        <city>St Nazaire</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut cancérologuie de la loire</name>
      <address>
        <city>St Priest en Jarez</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Claudius Régaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bretonneau</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2011</study_first_submitted>
  <study_first_submitted_qc>July 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2011</study_first_posted>
  <last_update_submitted>March 15, 2016</last_update_submitted>
  <last_update_submitted_qc>March 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endometrial cancer</keyword>
  <keyword>BKM</keyword>
  <keyword>monotherapy</keyword>
  <keyword>metastatic</keyword>
  <keyword>initial treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

